Summary
Novo Nordisk is unveiling a subscription model for self-pay customers of its popular GLP-1 weight loss drug Wegovy with much lower prices for both the injectable and the pill through three telehealth services. Its the latest effort by drug makers to reduce p
Source: TODAY
Exclusive AI-Powered News Insights (For Members only)
Disclaimer:This content is AI-generated from various trusted sources and is intended for informational purposes only. While we strive for accuracy, we encourage you to verify details independently. Use the contact button to share feedback on any inaccuracies—your input helps us improve!
